Zhang T - Search Results

1

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.

Brown LC, Zhu J, Desai K, Kinsey E, Kao C, Lee YH, Pabla S, Labriola MK, Tran J, Dragnev KH, Tafe LJ, Dayyani F, Gupta RT, McCall S, George DJ, Glenn ST, Nesline MK, George S, Zibelman M, Morrison C, Ornstein MC, Zhang T. Brown LC, et al. Among authors: zhang t. J Immunother Cancer. 2022 Oct;10(10):e005249. doi: 10.1136/jitc-2022-005249. J Immunother Cancer. 2022. PMID: 36252996 Free PMC article.

2

Mismatch repair gone awry: Management of Lynch syndrome.

Zhang T, Boswell EL, McCall SJ, Hsu DS. Zhang T, et al. Crit Rev Oncol Hematol. 2015 Mar;93(3):170-9. doi: 10.1016/j.critrevonc.2014.10.005. Epub 2014 Oct 12. Crit Rev Oncol Hematol. 2015. PMID: 25459670 Review.

3

Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.

Zhang T, Zhu J, George DJ, Armstrong AJ. Zhang T, et al. Expert Opin Pharmacother. 2015 Mar;16(4):473-85. doi: 10.1517/14656566.2015.995090. Epub 2014 Dec 23. Expert Opin Pharmacother. 2015. PMID: 25534660 Review.

4

Comparison of Quality Oncology Practice Initiative (QOPI) Measure Adherence Between Oncology Fellows, Advanced Practice Providers, and Attending Physicians.

Zhu J, Zhang T, Shah R, Kamal AH, Kelley MJ. Zhu J, et al. Among authors: zhang t. J Cancer Educ. 2015 Dec;30(4):774-8. doi: 10.1007/s13187-015-0798-z. J Cancer Educ. 2015. PMID: 25686787

5

Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.

Zhang T, Dhawan MS, Healy P, George DJ, Harrison MR, Oldan J, Chin B, Armstrong AJ. Zhang T, et al. Clin Genitourin Cancer. 2015 Aug;13(4):392-399. doi: 10.1016/j.clgc.2015.01.004. Epub 2015 Jan 24. Clin Genitourin Cancer. 2015. PMID: 25708161

6

A role for the androgen receptor in the treatment of male breast cancer.

Zhu J, Davis CT, Silberman S, Spector N, Zhang T. Zhu J, et al. Among authors: zhang t. Crit Rev Oncol Hematol. 2016 Feb;98:358-63. doi: 10.1016/j.critrevonc.2015.11.013. Epub 2015 Nov 26. Crit Rev Oncol Hematol. 2016. PMID: 26669267 Review.

7

Development of a Novel c-MET-Based CTC Detection Platform.

Zhang T, Boominathan R, Foulk B, Rao C, Kemeny G, Strickler JH, Abbruzzese JL, Harrison MR, Hsu DS, Healy P, Li J, Pi C, Prendergast KM, Hobbs C, Gemberling S, George DJ, Hurwitz HI, Connelly M, Garcia-Blanco MA, Armstrong AJ. Zhang T, et al. Mol Cancer Res. 2016 Jun;14(6):539-47. doi: 10.1158/1541-7786.MCR-16-0011. Epub 2016 Mar 7. Mol Cancer Res. 2016. PMID: 26951228

8

Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies.

Zhang T, Zhu J, George DJ, Nixon AB. Zhang T, et al. Urol Oncol. 2016 Nov;34(11):510-518. doi: 10.1016/j.urolonc.2016.06.020. Epub 2016 Aug 4. Urol Oncol. 2016. PMID: 27498927 Review.

9

Cabozantinib in genitourinary malignancies.

Zhang T, Park SE, Hong C, George DJ. Zhang T, et al. Future Oncol. 2017 Apr;13(8):755-765. doi: 10.2217/fon-2016-0358. Epub 2016 Nov 15. Future Oncol. 2017. PMID: 27842445 Review.

10

What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence.

Hu R, George DJ, Zhang T. Hu R, et al. Among authors: zhang t. Ther Adv Urol. 2016 Aug;8(4):272-278. doi: 10.1177/1756287216645314. Epub 2016 May 2. Ther Adv Urol. 2016. PMID: 27928429 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

35,379 results

Search Page